Medication info
Amosartan Q Tablets 5/100/20 mg (Amlodipine, Losartan, Rosuvastatin)

Amosartan Q Tablets 5/100/20 mg (Amlodipine, Losartan, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Camsylate›7.84mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tabletLosartan Potassium›100mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Pink oval film-coated tablets
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 201705686 · Approved 2017.07.14 · Insurance code 643507820

Summary

Main use
Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk
Who takes it
Adults
Adult dose
This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected extent of achievement of the treatment target with the combination compared with the individual components. The usual dose is 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min); however, administration of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ∘ Patients with reduced intravascular volume: Administration of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving treatment with high doses of diuretics). (See section 1. Warnings under Precautions for Use.) ∘ Patients with hepatic impairment: Administration of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or above, an initial dose of losartan of 25 mg once daily is recommended; therefore, administration of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. For patients taking the amlodipine/losartan combination concomitantly with rosuvastatin, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension; improvement of dyslipidemia; inhibition of atherosclerosis progression and reduction of cardiovascular disease risk

  • Essential hypertension
  • stage 2 hypertension
  • primary hypercholesterolemia
  • familial heterozygous hypercholesterolemia
  • mixed dyslipidemia
  • familial homozygous hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
View approved original text

This medication is used for reaching treatment goals in patients with essential hypertension or stage 2 hypertension whose blood pressure is not adequately controlled, by combining amlodipine and losartan. Additionally, the rosuvastatin component assists in lowering cholesterol levels and delaying the progression of atherosclerosis when dietary and exercise therapies are insufficient in patients with hypercholesterolemia and mixed dyslipidemia. Furthermore, it is used to reduce the risks of stroke, myocardial infarction, and arterial revascularization in adult patients with a high risk of cardiovascular disease. In summary, this medication is used to manage both hypertension and hyperlipidemia and reduce cardiovascular disease risks.

How to take

Adult dose

This medicine should be administered only to adults. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/losartan combination and rosuvastatin. ○ Amlodipine/losartan combination The recommended dose of the amlodipine/losartan combination is 1 tablet once daily in adults, taken with water, with or without food. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Before administering the amlodipine/losartan combination, it is recommended that the dose be adjusted using the individual components (amlodipine or losartan). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to the amlodipine/losartan combination may be considered as follows. - 5/50 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 50 mg monotherapy. - 5/100 mg: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 mg or losartan 100 mg monotherapy. Before administering the amlodipine/losartan combination as initial therapy to patients with stage 2 hypertension, the decision to administer it should take into account baseline blood pressure, target blood pressure, and the expected extent of achievement of the treatment target with the combination compared with the individual components. The usual dose is 5/50 mg once daily. If blood pressure is not adequately controlled after 2 weeks of treatment, the dose may be increased to 10/50 mg once daily. ∘ Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (e.g., creatinine clearance 20∼50mL/min); however, administration of the amlodipine/losartan combination is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. ∘ Patients with reduced intravascular volume: Administration of the amlodipine/losartan combination is not recommended in a small number of patients with reduced intravascular volume (e.g., patients receiving treatment with high doses of diuretics). (See section 1. Warnings under Precautions for Use.) ∘ Patients with hepatic impairment: Administration of the amlodipine/losartan combination is not recommended in patients with a history of hepatic impairment who require a reduced dose of losartan (e.g., 25 mg once daily). ∘ Older adults: In older adults aged 75 years or above, an initial dose of losartan of 25 mg once daily is recommended; therefore, administration of the amlodipine/losartan combination as initial therapy is not recommended. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and should continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, with or without food. The initial dose in adults is 5 mg once daily; the dose may be adjusted to a maintenance dose if a greater reduction in LDL cholesterol is required. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, the treatment goal, and the patient's response, and may be increased to a maximum of 20 mg daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or below, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of rosuvastatin is contraindicated in some of these patients. For patients taking the amlodipine/losartan combination concomitantly with rosuvastatin, they may be switched to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Precautions

This drug can seriously harm the fetus and newborn if taken during pregnancy. Especially in the second and third trimesters, it can affect renal development of the fetus leading to oligohydramnios and problems in lung formation. If pregnancy is confirmed, this medication should be discontinued immediately. Patients with low effective blood volume, such as those taking diuretics, may experience excessively low blood pressure when taking this medication for the first time, so caution is needed. Such patients should stabilize their condition before administering this drug. This medication should not be used in patients with allergies to specific components or a history of hereditary angioedema, in pregnant or potentially pregnant women, and in patients with severe liver or kidney disease. Caution is also advised in cases of muscle disorders or when combined with certain drugs as the risk of muscle damage may increase. Elderly patients, patients with hypotension, hyperkalemia, those with weakened liver or kidney function, and patients with heart valve diseases should also be careful when using this drug, undergoing regular checks of blood pressure, kidney function, and electrolyte levels. This medication can cause muscle pain or weakness, and rarely, severe muscle damage (rhabdomyolysis), so if any unusual muscle symptoms appear during treatment, the doctor must be notified immediately. This medication can interact with various drugs, so if other medications are being taken, it is essential to inform medical personnel, especially when used in conjunction with certain antibiotics, antifungals, immunosuppressants, and fibrate-class drugs. Pregnant or nursing women should not take this medication, and women planning to become pregnant should use appropriate contraception. Monitoring of blood pressure, liver function, kidney function, and blood potassium levels should be conducted regularly during the course of this medication to check for abnormalities. Moreover, if sudden dizziness, fainting, muscle pain, skin rashes, etc., occur, medical consultation should be sought immediately.

Side effects

Craniosynostosis, anuria, hypotension, renal failure, upper respiratory infection, dizziness, dyspepsia, lower gastrointestinal bleeding, postural dizziness, syncope, rhabdomyolysis, pancreatic cancer, dizziness, headache, drowsiness, cerebral infarction, weakness, chest discomfort, chest pain, early satiety, peripheral edema, depression, abdominal discomfort, nausea, gastroesophageal reflux disease, constipation, pruritus, urticaria, palpitations, flushing, orthostatic hypotension, facial flushing, dyspnea, cough, conjunctival injection, pollakiuria, angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, increased ALT, chest pain, myalgia, increased CK, weakness, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distention, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, fatigue, malaise, pain, weight gain, loss, hypotension, vasculitis, hypertonia, sensory impairment, paresthesia, peripheral neuropathy, syncope, taste disturbance, tremor, extrapyramidal disorders, erectile dysfunction, gynecomastia, changes in bowel habits, dry mouth, dyspepsia, gastritis, gingival hypertrophy, pancreatitis, vomiting, hyperglycemia, arthralgia, low back pain, muscle cramps, myalgia, leukopenia, thrombocytopenia, insomnia, mood changes, cough, dyspnea, rhinitis, alopecia, hyperhidrosis, purpura, skin discoloration, urticaria, toxic epidermal necrolysis syndrome, ringing in the ears, visual disturbances, increased urinary frequency, urinary disorders, nocturia, hepatitis, jaundice, increased liver enzymes, skin erythema, maculopapular rash, heaviness, warmth, impaired glucose tolerance, weakness, myocardial infarction, arrhythmia, chest pain, hypotension, sinoatrial block, atrioventricular block, abdominal discomfort, precordial pain, diarrhea, loose stools, constipation, skin flushing, angioedema, erythema multiforme, facial rash, lip, eyelid swelling, vasculitis, anaphylaxis-like syndrome, liver dysfunction, intestinal vascular edema, malaise, anemia, thrombocytopenia, myalgia, weakness, increased CK, elevated serum and urine myoglobin, taste disturbances, dry cough, erythema, hyperkalemia, hyponatremia, acute renal failure, oliguria, thrombocytopenia, increased serum creatinine, headache, dizziness, increased ALT, chest pain, myalgia, increased CK, weakness, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distention, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, angioedema, vasculitis, thrombocytopenia, anemia, muscle cramps, myalgia, insomnia, mood changes, alopecia, urticaria, toxic epidermal necrolysis syndrome, skin flushing, hypotension, edema, palpitations, orthostatic hypotension, facial flushing, dyspnea, cough, conjunctival injection, pollakiuria, angioedema, diabetes, constipation, nausea, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, eosinophilia and systemic symptoms associated drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disturbances, interstitial lung disease, sexual dysfunction, gynecomastia, increased ALT, chest pain, myalgia, increased CK, weakness, joint pain, fatigue, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distention, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. Additionally, it is safe to store the medication at room temperature between 1 and 30 degrees Celsius, avoiding excessively hot or cold locations.

Appearance and packaging

Appearance

Pink oval film-coated tablets

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.